Holen Sie sich die Stockscreener-App
5.49
3.00%
0.16
Handel nachbörslich:
5.44
-0.05
-0.91%
Schlusskurs vom Vortag:
$5.33
Offen:
$5.42
24-Stunden-Volumen:
1.26M
Relative Volume:
0.57
Marktkapitalisierung:
$988.68M
Einnahmen:
$850.00K
Nettoeinkommen (Verlust:
$-66.49M
KGV:
-12.66
EPS:
-0.4336
Netto-Cashflow:
$-49.17M
1W Leistung:
+3.20%
1M Leistung:
-6.79%
6M Leistung:
+57.31%
1J Leistung:
+153.58%
1-Tages-Spanne:
$5.39
$5.56
1-Wochen-Bereich:
$4.87
$5.56
52-Wochen-Spanne:
$1.33
$6.88
Compass Therapeutics Inc Stock (CMPX) Company Profile
Firmenname
Compass Therapeutics Inc
Sektor
Branche
Telefon
617-500-8099
Adresse
80 GUEST STREET, BOSTON
Compare CMPX vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CMPX
Compass Therapeutics Inc
|
5.49 | 959.87M | 850.00K | -66.49M | -49.17M | -0.4336 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Compass Therapeutics Inc Stock (CMPX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-13 | Eingeleitet | Craig Hallum | Buy |
| 2026-01-05 | Eingeleitet | William Blair | Outperform |
| 2025-12-03 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-12-03 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-12-03 | Eingeleitet | Citizens JMP | Mkt Outperform |
| 2025-07-01 | Fortgesetzt | Raymond James | Outperform |
| 2025-04-02 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-02-24 | Eingeleitet | Guggenheim | Buy |
| 2025-02-19 | Eingeleitet | Piper Sandler | Overweight |
| 2024-12-23 | Eingeleitet | D. Boral Capital | Buy |
| 2024-11-15 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-09-16 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2023-01-31 | Eingeleitet | Jefferies | Buy |
| 2023-01-27 | Eingeleitet | Stifel | Buy |
| 2022-05-23 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-03-15 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2022-01-19 | Eingeleitet | B. Riley Securities | Buy |
| 2021-12-22 | Eingeleitet | Raymond James | Outperform |
| 2021-12-20 | Eingeleitet | SVB Leerink | Outperform |
| 2021-12-15 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Compass Therapeutics Inc Aktie (CMPX) Neueste Nachrichten
Compass Therapeutics (NASDAQ:CMPX) Receives Buy Rating from Guggenheim - MarketBeat
Compass Therapeutics: Potential Here, But Patience Required (NASDAQ:CMPX) - Seeking Alpha
Compass Therapeutics, Inc. (NASDAQ:CMPX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Will Compass Therapeutics Inc stock go up in YEARWeekly Trade Summary & Fast Moving Market Watchlists - baoquankhu1.vn
Compass Therapeutics, Inc.Common Stock (NQ: CMPX - The Chronicle-Journal
Investment Advisor Bets Big on CMPX Stock, Adds 2.5 Million Shares, According to Latest SEC Filing - AOL.com
Here's why Compass Therapeutics, Inc. (CMPX) is a great momentum stock to buy - MSN
Compass Therapeutics Sees Major Institutional Investment Boost - National Today
Compass Therapeutics, Inc. $CMPX Stock Position Lifted by Suvretta Capital Management LLC - MarketBeat
Cantor Fitzgerald Maintains Overweight on CMPX (Compass Therapeutics, Inc.), Mar 2026 - Meyka
Is Compass Therapeutics' (CMPX) New ESOP Shelf Offering Reframing Its Equity-Funded R&D Strategy? - Sahm
Compass Therapeutics Inc celebrates women leadership driving innovation in science and therapy development - Traders Union
Compass Therapeutics stock rating reaffirmed at Citizens on trial progress By Investing.com - Investing.com Canada
What Compass Therapeutics (CMPX)'s Pipeline Progress And 2025 Losses Reveal About Its Oncology Strategy - Yahoo Finance
HC Wainwright Has Positive Estimate for CMPX FY2026 Earnings - MarketBeat
Analysts Have Conflicting Sentiments on These Healthcare Companies: Silence Therapeutics (SLN), RxSight (RXST) and Compass Therapeutics (CMPX) - The Globe and Mail
What is HC Wainwright's Estimate for CMPX Q1 Earnings? - MarketBeat
Compass Therapeutics Reports 2025 Financial Results and Provides Corporate Update - Sahm
Jefferies raises Compass Therapeutics stock price target on trial progress By Investing.com - Investing.com South Africa
Jefferies raises Compass Therapeutics stock price target on trial progress - Investing.com
Compass Therapeutics stock holds Outperform at William Blair ahead of trial data - Investing.com Canada
Raymond James reiterates Compass Therapeutics stock Outperform rating By Investing.com - Investing.com Canada
Raymond James reiterates Compass Therapeutics stock Outperform rating - Investing.com
Compass Therapeutics (NASDAQ:CMPX) Releases Earnings Results, Beats Estimates By $0.01 EPS - MarketBeat
Compass Therapeutics Inc. reports results for the quarter ended December 31Earnings Summary - TradingView
Compass Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Compass Therapeutics' Q4 Net Loss Narrows - marketscreener.com
Earnings Flash (CMPX) Compass Therapeutics Posts Q4 Net Loss $0.09 a Share, vs. FactSet Est of $0.09 Loss - marketscreener.com
Compass Therapeutics' 2025 net loss widens as R&D costs jump - TradingView
Compass Therapeutics 10-K: $0.0M Revenue, $(0.42) EPS on $(66.5)M Net Loss - TradingView
Compass Therapeutics, NAQ receives Investment Bank Analyst Rating Update By Investing.com - Investing.com Canada
How Palo Alto’s New Stake and Rising Institutional Ownership At Compass Therapeutics (CMPX) Has Changed Its Investment Story - simplywall.st
Assessing Compass Therapeutics (CMPX) Valuation As CTX-009 Gains Attention In Biliary Tract Cancer Market - Yahoo Finance
Monashee Investment Management Boosts Stake in Compass Therapeutics - National Today
Signal Recap: Does Compass Therapeutics Inc have a competitive edgeQuarterly Performance Summary & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Investment Firm Bets Big on Compass Therapeutics, Adds 2.5 Million Shares - National Today
Monashee Investment Management LLC Has $4.38 Million Stake in Compass Therapeutics, Inc. $CMPX - MarketBeat
Compass Therapeutics, Inc. (CMPX) Stock Analysis: Exploring a 130% Potential Upside in Biotech - DirectorsTalk Interviews
Compass Therapeutics earnings on deck as pivotal cancer data looms By Investing.com - Investing.com Canada
Compass Therapeutics earnings on deck as pivotal cancer data looms - Investing.com
Compass Therapeutics Inc. expected to post a loss of 9 cents a shareEarnings Preview - TradingView
Compass Therapeutics, Inc. (NASDAQ:CMPX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Zacks.com Spotlights Orla Mining, FIGS, and Compass Therapeutics - Intellectia AI
Is Compass Therapeutics Inc. stock forming a cup and handleJuly 2025 Retail & Reliable Entry Point Trade Alerts - mfd.ru
Compass Therapeutics Moves CTX-10726 Into the Clinic: What Early Investors Should Know - TipRanks
Compass Therapeutics (CMPX) to Release Quarterly Earnings on Thursday - MarketBeat
Finanzdaten der Compass Therapeutics Inc-Aktie (CMPX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):